CGEM (STOCKS)
Cullinan Therapeutics, Inc. Common Stock
$19.640000
+0.040000 (+0.20%)
Prev close: $19.600000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Nadim Ahmed
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,522.94M
- Employees
- 111
- P/E (TTM)
- -5.78
- P/B (TTM)
- 3.93
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.81 | $-0.83 | +0.0160 | +1.94% |
|
Mar 2026 (Q1)
|
$-0.75 | $-0.85 | +0.0953 | +11.27% |
|
Dec 2025 (Q4)
|
$-0.77 | $-0.83 | +0.0556 | +6.73% |
|
Sep 2025 (Q3)
|
$-0.77 | $-0.98 | +0.2064 | +21.14% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $221.81M |
| Research and Development | $171.47M |
| Other Operating Expenses | $50.03M |
| Operating Income/Loss | -$221.81M |
| Income/Loss From Continuing Operations After Tax | -$204.69M |
| Income/Loss From Continuing Operations Before Tax | -$204.69M |
| Net Income/Loss | -$204.69M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$204.69M |
| Net Income/Loss Available To Common Stockholders, Basic | -$204.69M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Assets | $363.79M |
| Current Assets | $341.97M |
| Cash | $334.50M |
| Prepaid Expenses | $7.44M |
| Other Current Assets | $38.00K |
| Noncurrent Assets | $21.81M |
| Fixed Assets | $263.00K |
| Other Non-current Assets | $21.55M |
| Liabilities | $42.03M |
| Current Liabilities | $40.63M |
| Accounts Payable | $3.73M |
| Other Current Liabilities | $36.90M |
| Noncurrent Liabilities | $1.41M |
| Equity | $321.75M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $321.75M |
| Liabilities And Equity | $363.79M |
| Net Cash Flow From Operating Activities | -$159.25M |
| Net Cash Flow From Operating Activities, Continuing | -$159.25M |
| Net Cash Flow From Investing Activities | $162.88M |
| Net Cash Flow From Investing Activities, Continuing | $162.88M |
| Net Cash Flow From Financing Activities | $2.20M |
| Net Cash Flow From Financing Activities, Continuing | $2.20M |
| Net Cash Flow | $5.82M |
| Net Cash Flow, Continuing | $5.82M |
| Comprehensive Income/Loss | -$205.43M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$204.54M |
| Other Comprehensive Income/Loss | $152.00K |